Tonix Q3 2026 product revenue rises to $17.2 million; net loss widens to $53.3 million
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, up from $3.3 million a year earlier, with TONMYA contributing $15.0 million. The net loss available to common stockholders widened to $53.3 million from $32.0 million, as research and development and selling, general and administrative expenses rose sharply. The company said its cash resources will meet its requirements into the early third quarter of 2027, a timeline shareholders will weigh against the larger losses.
Key points
- Net product revenue was $17.2 million versus $3.3 million a year earlier; TONMYA net revenue was $15.0 million, up 37% from the second quarter.
- Net loss available to common stockholders was $53.3 million, or $2.89 per share, compared with $32.0 million, or $3.59 per share, a year earlier.
- R&D expenses were $25.8 million and SG&A expenses were $45.6 million, compared with $9.3 million and $25.7 million a year earlier.
- Cash and cash equivalents were about $163 million as of September 30, 2026; the company expects them to fund operations into the early third quarter of 2027.
The filing
Written by AI on Nov 9, 2026, 7:32 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.